schliessen

Filtern

 

Bibliotheken

Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients

EndostarTM(YH-16)是中国烟台麦得津生物工程股份有限公司开发的新型重组人血管内皮抑素(rh-endostatin),临床前研究结果显示该药能抑制血管内皮细胞增殖、血管生成和肿瘤生长。Ⅰ、Ⅱ期临床结果证明该药单药临床应用安全有效。本研究的目的是评价YH-16联合长春瑞滨和顺铂(NP)治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 2003年4月2004年6月,493例一般状况评分为02,经病理和细胞学确诊的Ⅲ/Ⅳ期NSCLC患者进入NP联合YH-16与NP联合安慰剂的随机、双盲、对照、多中心临床研究。研究的终点目标是有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP... Full description

Journal Title: Zhongguo Fei Ai Za Zhi 2005, Vol.8(4), pp.283-290
Main Author: Wang, Jinwan
Other Authors: Sun, Yan , Liu, Yongyu , Yu, Qitao , Zhang, Yiping , LI, Kai , Zhu, Yunzhong , Zhou, Qinghua , Hou, Mei , Guan, Zhongzhen , LI, Weilian , Wu, Zhuang , Wang, Donglin , Liang, Houjie , Qin, Fengzhan , Lu, Huishan , Liu, Xiaoqing , Sun, Hong , Zhang, Yanjun , Wang
Format: Electronic Article Electronic Article
Language: chi
Subjects:
ID: ISSN: 10093419 ; E-ISSN: 19996187 ; DOI: 10.3779/cjlc.v8i4.1926
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest2127694428
title: Results of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
format: Article
creator:
  • Wang, Jinwan
  • Sun, Yan
  • Liu, Yongyu
  • Yu, Qitao
  • Zhang, Yiping
  • LI, Kai
  • Zhu, Yunzhong
  • Zhou, Qinghua
  • Hou, Mei
  • Guan, Zhongzhen
  • LI, Weilian
  • Wu, Zhuang
  • Wang, Donglin
  • Liang, Houjie
  • Qin, Fengzhan
  • Lu, Huishan
  • Liu, Xiaoqing
  • Sun, Hong
  • Zhang, Yanjun
  • Wang
subjects:
  • Lung Cancer
  • Response Rates
ispartof: Zhongguo Fei Ai Za Zhi, 2005, Vol.8(4), pp.283-290
description: EndostarTM(YH-16)是中国烟台麦得津生物工程股份有限公司开发的新型重组人血管内皮抑素(rh-endostatin),临床前研究结果显示该药能抑制血管内皮细胞增殖、血管生成和肿瘤生长。Ⅰ、Ⅱ期临床结果证明该药单药临床应用安全有效。本研究的目的是评价YH-16联合长春瑞滨和顺铂(NP)治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 2003年4月2004年6月,493例一般状况评分为02,经病理和细胞学确诊的Ⅲ/Ⅳ期NSCLC患者进入NP联合YH-16与NP联合安慰剂的随机、双盲、对照、多中心临床研究。研究的终点目标是有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)以及安全性。结果...
language: chi
source:
identifier: ISSN: 10093419 ; E-ISSN: 19996187 ; DOI: 10.3779/cjlc.v8i4.1926
fulltext: fulltext_linktorsrc
issn:
  • 10093419
  • 1009-3419
  • 19996187
  • 1999-6187
url: Link


@attributes
ID1447625537
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid2127694428
sourceidproquest
recordidTN_proquest2127694428
sourcesystemPC
pqid2127694428
display
typearticle
titleResults of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
creatorWang, Jinwan ; Sun, Yan ; Liu, Yongyu ; Yu, Qitao ; Zhang, Yiping ; LI, Kai ; Zhu, Yunzhong ; Zhou, Qinghua ; Hou, Mei ; Guan, Zhongzhen ; LI, Weilian ; Wu, Zhuang ; Wang, Donglin ; Liang, Houjie ; Qin, Fengzhan ; Lu, Huishan ; Liu, Xiaoqing ; Sun, Hong ; Zhang, Yanjun ; Wang
ispartofZhongguo Fei Ai Za Zhi, 2005, Vol.8(4), pp.283-290
identifier
subjectLung Cancer ; Response Rates
descriptionEndostarTM(YH-16)是中国烟台麦得津生物工程股份有限公司开发的新型重组人血管内皮抑素(rh-endostatin),临床前研究结果显示该药能抑制血管内皮细胞增殖、血管生成和肿瘤生长。Ⅰ、Ⅱ期临床结果证明该药单药临床应用安全有效。本研究的目的是评价YH-16联合长春瑞滨和顺铂(NP)治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 2003年4月2004年6月,493例一般状况评分为02,经病理和细胞学确诊的Ⅲ/Ⅳ期NSCLC患者进入NP联合YH-16与NP联合安慰剂的随机、双盲、对照、多中心临床研究。研究的终点目标是有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)以及安全性。结果...
languagechi
source
version3
oafree_for_read
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttp://search.proquest.com/docview/2127694428/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Wang, Jinwan
1Sun, Yan
2Liu, Yongyu
3Yu, Qitao
4Zhang, Yiping
5LI, Kai
6Zhu, Yunzhong
7Zhou, Qinghua
8Hou, Mei
9Guan, Zhongzhen
10LI, Weilian
11Wu, Zhuang
12Wang, Donglin
13Liang, Houjie
14Qin, Fengzhan
15Lu, Huishan
16Liu, Xiaoqing
17Sun, Hong
18Zhang, Yanjun
19Wang, Jiejun
20Luo, Suxia
21Yang, Ruihe
22Tu, Yuanrong
23Wang, Xiuwen
24Song, Shuping
25Zhou, Jingmin
26You, Lifen
27Wang, Jing
28Chen, Yao
titleResults of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
descriptionEndostarTM(YH-16)是中国烟台麦得津生物工程股份有限公司开发的新型重组人血管内皮抑素(rh-endostatin),临床前研究结果显示该药能抑制血管内皮细胞增殖、血管生成和肿瘤生长。Ⅰ、Ⅱ期临床结果证明该药单药临床应用安全有效。本研究的目的是评价YH-16联合长春瑞滨和顺铂(NP)治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 2003年4月2004年6月,493例一般状况评分为02,经病理和细胞学确诊的Ⅲ/Ⅳ期NSCLC患者进入NP联合YH-16与NP联合安慰剂的随机、双盲、对照、多中心临床研究。研究的终点目标是有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)以及安全性。结果...
subject
0Lung Cancer
1Response Rates
general
0Chinese
1Chinese Anti-Cancer Association Chinese Antituberculosis Association
210.3779/cjlc.v8i4.1926
3East & South Asia Database
4Publicly Available Content Database
5ProQuest Central (new)
6ProQuest Central Korea
7ProQuest Central Essentials
8ProQuest One Academic
sourceidproquest
recordidproquest2127694428
issn
010093419
11009-3419
219996187
31999-6187
rsrctypearticle
creationdate2005
addtitleZhongguo Fei Ai Za Zhi
searchscope
01008875
11008886
21009049
31009127
41009240
510000255
610000256
710000258
810000268
910000281
1010000348
1110000360
12proquest
scope
01008875
11008886
21009049
31009127
41009240
510000255
610000256
710000258
810000268
910000281
1010000348
1110000360
12proquest
lsr43
01008875true
11008886true
21009049true
31009127true
41009240true
510000255true
610000256true
710000258true
810000268true
910000281true
1010000348true
1110000360true
startdate20050701
enddate20050701
citationpf 283 pt 290 vol 8 issue 4
lsr30VSR-Enriched:[pqid, doi]
sort
titleResults of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
authorWang, Jinwan ; Sun, Yan ; Liu, Yongyu ; Yu, Qitao ; Zhang, Yiping ; LI, Kai ; Zhu, Yunzhong ; Zhou, Qinghua ; Hou, Mei ; Guan, Zhongzhen ; LI, Weilian ; Wu, Zhuang ; Wang, Donglin ; Liang, Houjie ; Qin, Fengzhan ; Lu, Huishan ; Liu, Xiaoqing ; Sun, Hong ; Zhang, Yanjun ; Wang
creationdate20050701
lso0120050701
facets
frbrgroupid8273925687477407324
frbrtype5
newrecords20181106
languagechi
creationdate2005
topic
0Lung Cancer
1Response Rates
collection
0East & South Asia Database
1Publicly Available Content Database
2ProQuest Central (new)
3ProQuest Central Korea
4ProQuest Central Essentials
5ProQuest One Academic
prefilterarticles
rsrctypearticles
creatorcontrib
0Wang, Jinwan
1Sun, Yan
2Liu, Yongyu
3Yu, Qitao
4Zhang, Yiping
5LI, Kai
6Zhu, Yunzhong
7Zhou, Qinghua
8Hou, Mei
9Guan, Zhongzhen
10LI, Weilian
11Wu, Zhuang
12Wang, Donglin
13Liang, Houjie
14Qin, Fengzhan
15Lu, Huishan
16Liu, Xiaoqing
17Sun, Hong
18Zhang, Yanjun
19Wang, Jiejun
20Luo, Suxia
21Yang, Ruihe
22Tu, Yuanrong
23Wang, Xiuwen
24Song, Shuping
25Zhou, Jingmin
26You, Lifen
27Wang, Jing
28Chen, Yao
jtitleZhongguo Fei Ai Za Zhi
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0WANG
1SUN
2LIU
3YU
4ZHANG
5LI
6ZHU
7ZHOU
8HOU
9GUAN
10Wu
11LIANG
12QIN
13LU
14LUO
15YANG
16TU
17SONG
18YOU
19Chen
aufirst
0Jinwan
1Yan
2Yongyu
3Qitao
4Yiping
5Kai
6Yunzhong
7Qinghua
8Mei
9Zhongzhen
10Weilian
11ZHUANG
12Donglin
13Houjie
14Fengzhan
15Huishan
16Xiaoqing
17Hong
18Yanjun
19Jiejun
20Suxia
21Ruihe
22Yuanrong
23Xiuwen
24Shuping
25Jingmin
26Lifen
27Jing
28YAO
au
0Wang, Jinwan
1Sun, Yan
2Liu, Yongyu
3Yu, Qitao
4Zhang, Yiping
5LI, Kai
6Zhu, Yunzhong
7Zhou, Qinghua
8Hou, Mei
9Guan, Zhongzhen
10LI, Weilian
11Wu, Zhuang
12Wang, Donglin
13Liang, Houjie
14Qin, Fengzhan
15Lu, Huishan
16Liu, Xiaoqing
17Sun, Hong
18Zhang, Yanjun
19Wang, Jiejun
20Luo, Suxia
21Yang, Ruihe
22Tu, Yuanrong
23Wang, Xiuwen
24Song, Shuping
25Zhou, Jingmin
26You, Lifen
27Wang, Jing
28Chen, Yao
atitleResults of randomized, multicenter, double-blind phase Ⅲ trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
jtitleZhongguo Fei Ai Za Zhi
risdate20050701
volume8
issue4
spage283
epage290
pages283-290
issn10093419
eissn19996187
formatjournal
genrearticle
ristypeJOUR
abstractEndostarTM(YH-16)是中国烟台麦得津生物工程股份有限公司开发的新型重组人血管内皮抑素(rh-endostatin),临床前研究结果显示该药能抑制血管内皮细胞增殖、血管生成和肿瘤生长。Ⅰ、Ⅱ期临床结果证明该药单药临床应用安全有效。本研究的目的是评价YH-16联合长春瑞滨和顺铂(NP)治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 2003年4月2004年6月,493例一般状况评分为02,经病理和细胞学确诊的Ⅲ/Ⅳ期NSCLC患者进入NP联合YH-16与NP联合安慰剂的随机、双盲、对照、多中心临床研究。研究的终点目标是有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)以及安全性。结果...
copTianjin
pubChinese Anti-Cancer Association Chinese Antituberculosis Association
doi10.3779/j.issn.1009-3419.2005.04.07
urlhttp://search.proquest.com/docview/2127694428/
oafree_for_read
date2005-07-01